- Home
- SFBS vs DNLI Comparison
SFBS vs DNLI Comparison
Compare SFBS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SFBS | DNLI |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SFBS | DNLI |
|---|---|---|
| Price | $89.39 | $24.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $93.00 | $34.33 |
| AVG Volume (30 Days) | 275.4K | ★ 1.7M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ 21.63 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.30 | N/A |
| Revenue Next Year | $10.30 | $408.85 |
| P/E Ratio | $58.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $67.20 | $12.58 |
| 52 Week High | $90.64 | $27.30 |
Technical Indicators
Market Signals| Indicator | SFBS | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 50.75 |
| Support Level | $78.72 | $18.27 |
| Resistance Level | N/A | $27.30 |
| Average True Range (ATR) | 1.94 | 1.32 |
| MACD | 0.09 | -0.20 |
| Stochastic Oscillator | 91.45 | 36.08 |
Price Performance
Historical ComparisonAbout SFBS ServisFirst Bancshares Inc.
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.